Pacific Biosciences Of California (PACB) Profit After Tax Growth (3y) (2013 - 2026)
Pacific Biosciences Of California (PACB) Profit After Tax Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -12.28% |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | 20.02% |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | 49.66% |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | -7.65% |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 29.05% |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | 9.79% |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | 97.37% |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | 15.46% |
| 10 | Pacific Biosciences Of California | 419.38 Mn | 182.51 Mn | 12.64 Mn | 13.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.88% |
| Mar 31, 2026 | 54.53% |
| Dec 31, 2025 | 21.79% |
| Sep 30, 2025 | 21.34% |
| Jun 30, 2025 | 88.31% |
| Mar 31, 2025 | 92.14% |
| Dec 31, 2024 | 26.31% |
| Jun 30, 2024 | -61.69% |
| Mar 31, 2024 | 3.45% |
| Dec 31, 2023 | -45.27% |
| Sep 30, 2023 | -40.69% |
| Jun 30, 2023 | -45.07% |
| Mar 31, 2023 | -312.89% |
| Dec 31, 2022 | -875.15% |
| Sep 30, 2022 | -38.74% |
| Jun 30, 2022 | -42.65% |
| Mar 31, 2022 | -40.78% |
| Dec 31, 2021 | -31.06% |
| Jun 30, 2021 | -22.07% |
| Mar 31, 2021 | -53.49% |